DJIA 18,010.68 -115.44 -0.64%
NASDAQ 5,070.03 -27.95 -0.55%
S&P 500 2,107.39 -13.40 -0.63%
market minute promo

9.89 0.55 (5.89%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ACHN $9.89 5.89%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $9.29
Previous Close $9.34
Daily Range $9.27 - $9.91
52-Week Range $2.65 - $16.87
Market Cap $1.2B
P/E Ratio -13.34
Dividend (Yield) $0.00 (0.0%)
Volume 4,964,243
Average Daily Volume 3,852,814
Current FY EPS -$0.78

Sector

Healthcare

Industry

Drug Makers

ACHILLION PHARMACEUTICALS, INC. (ACHN) Description

A biopharmaceutical company focuses on the discovery, development and commercialization of innovative treatments for infectious diseases Website: http://www.achillion.com/

News & Commentary Rss Feed

Gilead's Sustainable Competitive Advantage

Gilead Sciences' long-term growth is being doubted by the Street because of the uncertainty surrounding the hep C market going forward. The biotech's top notch CEO John Martin, however, should be reason enough for investors to believe that company's best days lie ahead. Here's why.

The Janssen-Achillion Deal Proves My Short Thesis

Seeking Alpha's Biotech Weekly: J&J-Achillion Vs. Gilead, MannKind's Marketing, And More

J&J (JNJ) to File for More than 10 New Products by 2019 - Analyst Blog

UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc. ...

Johnson & Johnson Just Stepped Up Its Hepatitis C Game

Johnson & Johnson has inked a licensing deal with Achillion Pharmaceuticals that could threaten Gilead Sciences market share in hepatitis C. Should Gilead investors worry?

The Zacks Analyst Blog Highlights: Eleven Biotherapeutics, bluebird, Agios, Acceleron and Achillion

The Zacks Analyst Blog Highlights: Eleven Biotherapeutics, bluebird, Agios, Acceleron and Achillion - Press Releases

Gilead, Merck And Achillion/J&J Square Off In An HCV 'Nuc'lear Showdown

What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors?

Biotech Stock Roundup: Eleven Bio Slumps on Eye Drug Data, Achillion Signs Deal with J&J - Analyst B

Biotech Stock Roundup: Eleven Bio Slumps on Eye Drug Data, Achillion Signs Deal with J&J - Analyst Blog

See More ACHN News...

ACHN's Top Competitors

ACHN $9.89 (5.89%)
Current stock: ACHN
AMGN $156.26 (-0.69%)
Current stock: AMGN
GILD $112.27 (-0.51%)
Current stock: GILD
BIIB $396.99 (-0.78%)
Current stock: BIIB